NCT03593499No Longer Available不适用
Expanded Access to Omaveloxolone for Melanoma for Patients Previously Enrolled in 408-C-1401
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- No Longer Available
- 发起方
- Biogen
研究概览
简要总结
This is an expanded access program for eligible participants and is designed to provide access to omaveloxolone for the treatment of unresectable or metastatic melanoma to patients who previously participated in the 408-C-1401 (REVEAL) study. To be considered for expanded access, a Principal Investigator from the REVEAL trial should submit a request to Reata Pharmaceuticals on behalf of the individual patient.
详细描述
Study Sponsor, originally Reata Pharmaceuticals, Inc., is now Reata Pharmaceuticals, Inc., a wholly owned subsidiary of Biogen.
研究设计
- 研究类型
- Expanded Access
入排标准
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
研究者
相似试验
No Longer Available
不适用
Expanded Access to ElezanumabAcute Spinal Cord Injury (SCI)NCT04278235AbbVie
Available
不适用
Expanded Access to VenetoclaxChronic Lymphocytic Leukemia (CLL)Acute Myeloid Leukemia (AML)Non-Hodgkin's LymphomaAcute Lymphoblastic Leukemia (ALL)Plasma Cell LeukemiaMultiple MyelomaAmyloidosisNCT03123029AbbVie
No Longer Available
不适用
Expanded Access to Bimatoprost (Durysta)Open-angle GlaucomaNCT05338606AbbVie
No Longer Available
不适用
Expanded Access Program for Ocrelizumab in Participants With Primary Progressive Multiple SclerosisMultiple SclerosisNCT02807285Genentech, Inc.
No Longer Available
不适用
Expanded Access for MarizomibSolid TumorNCT04644107Celgene